Evidence map›Paper›PMID 30094352›Full record

ArticleClinical and translational radiation oncology2018

Verification of HE-based CTV in laryngeal and hypopharyngeal cancer using pan-cytokeratin.

Hans Ligtenberg, Stefan M Willems, Lilian N Ruiter, Elise Anne Jager, Chris H J Terhaard, Cornelis P J Raaijmakers, Marielle E P Philippens

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hans LigtenbergDepartment of Radiotherapy, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Stefan M WillemsDepartment of Pathology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Lilian N RuiterDepartment of Pathology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Elise Anne JagerDepartment of Radiotherapy, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Chris H J TerhaardDepartment of Radiotherapy, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Cornelis P J RaaijmakersDepartment of Radiotherapy, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Marielle E P PhilippensDepartment of Radiotherapy, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
University Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor accurate target definition, we determined margins for the clinical target volume (CTV) for laryngeal and hypopharyngeal cancer in computed tomography (CT, 4.3 mm), magnetic resonance imaging (MR, 6.1 mm) and fluorodeoxyglucose (FDG)-positron emission tomography (PET, 5.2 mm). Previously, we used Hematoxylin-eosin (HE) stained whole-mount sections of total laryngectomy specimens as gold standard to define CTV margins. In the present study, we verified the HE-based tumor delineation with staining for pan-cytokeratin, specific for squamous cell carcinoma.

methodsTwenty-seven patients with a T3/T4 laryngeal hypopharyngeal tumor were included. From each patient, a total laryngectomy specimen was obtained. Four subsequent 3-mm thick slices containing tumor were selected of which 4-µm thick whole-mount sections were obtained and stained with HE and for pan-cytokeratin CK-AE1/3. Tumors were microscopically delineated on both sections by an experienced head-and-neck pathologist. Tumor delineations were compared using the conformity index (CI) and the distance between both contours.

resultsThe CI between HE-based and CK-AE1/3-based tumor delineations was 0.87. The maximum and 95th percentile (p95) extent of the HE-based tumor delineations from the CK-AE1/3-based tumor delineations were 1.7 mm and 0.7 mm, respectively. The maximum and p95 extent of the CK-AE1/3-based tumor delineations from the HE-based tumor delineations was 1.9 mm and 0.8 mm, respectively.

conclusionsHistopathological assessment of tumor outline on standard HE-stained sections is comparable to microscopic tumor extent based on squamous cell specific pan-cytokeratin staining. Therefore, CTV margins based on HE based tumor contour will be adequate.

Indexed as

CI, conformity indexCK-AE1/3, cytokeratin AE1/3 antibodiesCT, computed tomographyCTV, clinical target volumeDAB, diaminobenzidineFDG-PET, fluoro-deoxyglucose positron emission tomographyGTV, gross tumor volumeHEHead and neckHE, hematoxylin-eosinHIER, heat-induced epitope retrievalHistopathologyMRI, magnetic resonance imagingp95, 95th percentilePan-cytokeratinPBS, phosphate-buffered salineSCC, squamous cell carcinomaSquamous cell carcinomaTarget definitionTLE, total laryngectomyTME, tumor microenvironment

Identifiers

PMID30094352
PMCPMC6077173
OpenAlexW2815751449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.